J Neurol Surg B Skull Base 2020; 81(06): 664-672
DOI: 10.1055/s-0039-1694967
Original Article

Squamous Cell Carcinoma of the Paranasal Sinuses: A Single Center Experience

1   Department of Neurosurgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway
2   Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
,
Terje Osnes
2   Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
3   Department of Otorhinolaryngology, Head and Neck Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway
,
Åse Bratland
4   Department of Oncology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
,
Torstein R. Meling
1   Department of Neurosurgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway
2   Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
5   Service de Neurochirurgie, Département des Neurosciences Cliniques, Hopitaux Universitaires de Genève, Genève, Switzerland
6   Faculty of Medicine, University of Geneva, Geneva, Switzerland
› Author Affiliations
Funding This research did not receive any specific grant from funding agencies in the public, commercial, or non-for-profit sectors.

Abstract

Objective Squamous cell carcinoma (SCC) of the paranasal sinuses is usually diagnosed at an advanced stage, making curative therapy difficult. The goal of this study was to evaluate the management and outcomes of patients with SCC treated at our institution.

Methods In a population-based consecutive prospective cohort, we conducted an analysis of all patients treated for SCC between 1988 and 2017.

Results A total of 72 patients were included, follow-up was 100%. Mean follow-up was 57 months for the entire cohort, and 108 months for patients with no evidence of disease. Eighty-two percent of all patients had high-stage (T4) disease. Fifty-seven patients underwent treatment with curative intent; consisting of surgery with or without oncologic treatment in 34, and of oncologic treatment only in 23 cases. Fifteen patients received palliative treatment. The rates of overall survival for the entire cohort were 55% at 2, 41% at 5, and 32% at 10 years, and corresponding disease-specific survival (DSS) rates were 55, 45, and 34%, respectively. DSS rates after surgical treatment with curative intent were 81% at 2, 65% at 5, and 54% at 10 years. Retromaxillary involvement and nonradical surgery were negative prognostic factors. Best survival was achieved with the combination of radical surgery and adjuvant oncologic treatment.

Conclusion Surgical resection with a curative intent yielded 65% at 5-year DSS even in this cohort of patients with high-stage SCC and is still considered as the treatment of choice, preferably in combination with adjuvant radiation therapy and chemotherapy.



Publication History

Received: 29 April 2019

Accepted: 03 July 2019

Article published online:
05 August 2019

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Lund VJ, Stammberger H, Nicolai P. et al; European Rhinologic Society Advisory Board on Endoscopic Techniques in the Management of Nose, Paranasal Sinus and Skull Base Tumours. European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. Rhinol Suppl 2010; 22: 1-143
  • 2 von Buchwald C, Bradley PJ. Risks of malignancy in inverted papilloma of the nose and paranasal sinuses. Curr Opin Otolaryngol Head Neck Surg 2007; 15 (02) 95-98
  • 3 Norlander T, Frödin JE, Silfverswärd C, Anggård A. Decreasing incidence of malignant tumors of the paranasal sinuses in Sweden. An analysis of 141 consecutive cases at Karolinska Hospital from 1960 to 1980. Ann Otol Rhinol Laryngol 2003; 112 (03) 236-241
  • 4 Harbo G, Grau C, Bundgaard T. et al. Cancer of the nasal cavity and paranasal sinuses. A clinico-pathological study of 277 patients. Acta Oncol 1997; 36 (01) 45-50
  • 5 Grau C, Jakobsen MH, Harbo G. et al. Sino-nasal cancer in Denmark 1982-1991--a nationwide survey. Acta Oncol 2001; 40 (01) 19-23
  • 6 Osguthorpe JD. Sinus neoplasia. Arch Otolaryngol Head Neck Surg 1994; 120 (01) 19-25
  • 7 Carrau RL, Myers EM, Johnson JT. Paranasal sinus carcinoma--diagnosis, treatment, and prognosis. Oncology (Williston Park) 1992; 6 (01) 43-50 , discussion 55–56
  • 8 de Almeida JR, Su SY, Koutourousiou M. et al. Endonasal endoscopic surgery for squamous cell carcinoma of the sinonasal cavities and skull base: oncologic outcomes based on treatment strategy and tumor etiology. Head Neck 2015; 37 (08) 1163-1169
  • 9 Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB. Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck 2002; 24 (09) 821-829
  • 10 Bridgeman AM, Murphy MJ, Sizeland A, Wiesenfeld D. Midfacial tumours: a review of 72 cases. Br J Oral Maxillofac Surg 2000; 38 (02) 94-103
  • 11 Jun BC, Song SW, Park CS, Lee DH, Cho KJ, Cho JH. The analysis of maxillary sinus aeration according to aging process; volume assessment by 3-dimensional reconstruction by high-resolutional CT scanning. Otolaryngol Head Neck Surg 2005; 132 (03) 429-434
  • 12 Bobinskas AM, Wiesenfeld D, Chandu A. Influence of the site of origin on the outcome of squamous cell carcinoma of the maxilla-oral versus sinus. Int J Oral Maxillofac Surg 2014; 43 (02) 137-141
  • 13 König M, Osnes T, Jebsen P, Meling TR. Craniofacial resection of malignant tumors of the anterior skull base: a case series and a systematic review. Acta Neurochir (Wien) 2018; 160 (12) 2339-2348
  • 14 König M, Osnes TA, Lobmaier I. et al. Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years. Neurosurg Rev 2017; 40 (03) 449-460
  • 15 König M, Osnes T, Jebsen P, Evensen JF, Meling TR. Olfactory neuroblastoma: a single-center experience. Neurosurg Rev 2018; 41 (01) 323-331
  • 16 Waldron J, Witterick I. Paranasal sinus cancer: caveats and controversies. World J Surg 2003; 27 (07) 849-855
  • 17 Ansa B, Goodman M, Ward K. et al. Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009. Cancer 2013; 119 (14) 2602-2610
  • 18 Tanvetyanon T, Qin D, Padhya T, Kapoor R, McCaffrey J, Trotti A. Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis. Am J Otolaryngol 2009; 30 (01) 38-43
  • 19 Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, 7th ed. France: Springer; 2010
  • 20 Zange J, Schuchardt K. Rhinologische und plastiche Operationen auf Grenzgebieten mit der Ophthalmologie und Chirurgie. In: Thiel R. ed. Ophthalmologische Operationslehre. Leipzig: Thieme; 1950: 1302
  • 21 Claus F, Boterberg T, Ost P, De Neve W. Short term toxicity profile for 32 sinonasal cancer patients treated with IMRT. Can we avoid dry eye syndrome?. Radiother Oncol 2002; 64 (02) 205-208
  • 22 Claus F, De Gersem W, De Wagter C. et al. An implementation strategy for IMRT of ethmoid sinus cancer with bilateral sparing of the optic pathways. Int J Radiat Oncol Biol Phys 2001; 51 (02) 318-331
  • 23 Shukovsky LJ, Fletcher GH. Retinal and optic nerve complications in a high dose irradiation technique of ethmoid sinus and nasal cavity. Radiology 1972; 104 (03) 629-634
  • 24 Parsons JT, Mendenhall WM, Mancuso AA, Cassisi NJ, Million RR. Malignant tumors of the nasal cavity and ethmoid and sphenoid sinuses. Int J Radiat Oncol Biol Phys 1988; 14 (01) 11-22
  • 25 Robbins KT, Storniolo AM, Kerber C, Seagren S, Berson A, Howell SB. Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck 1992; 14 (05) 364-371
  • 26 National Guidelines for the treatment of Head and Neck Cancer Copenhagen. Denmark: Danish Head and Neck Cancer Group (DAHANCA); 2018. . Accessed July 26, 2019 at: www.dahanca.oncology.dk
  • 27 Bernier J, Domenge C, Ozsahin M. et al; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350 (19) 1945-1952
  • 28 Cooper JS, Pajak TF, Forastiere AA. et al; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350 (19) 1937-1944
  • 29 Cooper JS, Zhang Q, Pajak TF. et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012; 84 (05) 1198-1205
  • 30 Ono T, Tanaka N, Umeno H. et al. Treatment outcomes of locally advanced squamous cell carcinoma of the maxillary sinus treated with chemoradioselection using superselective intra-arterial cisplatin and concomitant radiation: implications for prognostic factors. J Craniomaxillofac Surg 2017; 45 (12) 2128-2134
  • 31 Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
  • 32 Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50 (03) 163-170
  • 33 Cox D. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220
  • 34 Fisher RA. On the interpretation of X2 from contingency tables, and the calculation of p. J R Stat Soc 1922; 85 (01) 87-94
  • 35 Kermer C, Poeschl PW, Wutzl A, Schopper C, Klug C, Poeschl E. Surgical treatment of squamous cell carcinoma of the maxilla and nasal sinuses. J Oral Maxillofac Surg 2008; 66 (12) 2449-2453
  • 36 Nishino H, Miyata M, Morita M, Ishikawa K, Kanazawa T, Ichimura K. Combined therapy with conservative surgery, radiotherapy, and regional chemotherapy for maxillary sinus carcinoma. Cancer 2000; 89 (09) 1925-1932
  • 37 Chen NX, Chen L, Wang JL. et al. A clinical study of multimodal treatment for orbital organ preservation in locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinus. Jpn J Clin Oncol 2016; 46 (08) 727-734
  • 38 Patel SG, Singh B, Polluri A. et al. Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer 2003; 98 (06) 1179-1187
  • 39 Ganly I, Patel SG, Singh B. et al. Craniofacial resection for malignant paranasal sinus tumors: report of an International Collaborative Study. Head Neck 2005; 27 (07) 575-584
  • 40 McKay SP, Shibuya TY, Armstrong WB. et al. Cell carcinoma of the paranasal sinuses and skull base. Am J Otolaryngol 2007; 28 (05) 294-301
  • 41 Lee CH, Hur DG, Roh HJ. et al. Survival rates of sinonasal squamous cell carcinoma with the new AJCC staging system. Arch Otolaryngol Head Neck Surg 2007; 133 (02) 131-134
  • 42 Mine S, Saeki N, Horiguchi K, Hanazawa T, Okamoto Y. Craniofacial resection for sinonasal malignant tumors: statistical analysis of surgical outcome over 17 years at a single institution. Skull Base 2011; 21 (04) 243-248
  • 43 Buchmann L, Larsen C, Pollack A, Tawfik O, Sykes K, Hoover LA. Endoscopic techniques in resection of anterior skull base/paranasal sinus malignancies. Laryngoscope 2006; 116 (10) 1749-1754
  • 44 Shipchandler TZ, Batra PS, Citardi MJ, Bolger WE, Lanza DC. Outcomes for endoscopic resection of sinonasal squamous cell carcinoma. Laryngoscope 2005; 115 (11) 1983-1987
  • 45 Nicolai P, Battaglia P, Bignami M. et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol 2008; 22 (03) 308-316
  • 46 Stern SJ, Goepfert H, Clayman G. et al. Squamous cell carcinoma of the maxillary sinus. Arch Otolaryngol Head Neck Surg 1993; 119 (09) 964-969
  • 47 Le QT, Fu KK, Kaplan M, Terris DJ, Fee WE, Goffinet DR. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems. Cancer 1999; 86 (09) 1700-1711
  • 48 Myers LL, Nussenbaum B, Bradford CR, Teknos TN, Esclamado RM, Wolf GT. Paranasal sinus malignancies: an 18-year single institution experience. Laryngoscope 2002; 112 (11) 1964-1969
  • 49 Hayashi T, Nonaka S, Bandoh N, Kobayashi Y, Imada M, Harabuchi Y. Treatment outcome of maxillary sinus squamous cell carcinoma. Cancer 2001; 92 (06) 1495-1503
  • 50 Carrillo JF, Carrillo LC, Cano A. et al. Retrospective cohort study of prognostic factors in patients with oral cavity and oropharyngeal squamous cell carcinoma. Head Neck 2016; 38 (04) 536-541
  • 51 Carrillo JF, Güemes A, Ramírez-Ortega MC, Oñate-Ocaña LF. Prognostic factors in maxillary sinus and nasal cavity carcinoma. Eur J Surg Oncol 2005; 31 (10) 1206-1212
  • 52 Stavrianos SD, Camilleri IG, McLean NR, Piggot TA, Kelly CG, Soames JV. Malignant tumours of the maxillary complex: an 18-year review. Br J Plast Surg 1998; 51 (08) 584-588
  • 53 Porceddu S, Martin J, Shanker G. et al. Paranasal sinus tumors: Peter MacCallum Cancer Institute experience. Head Neck 2004; 26 (04) 322-330
  • 54 Airoldi M, Garzaro M, Valente G. et al. Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region. Oncology 2009; 76 (04) 262-269